Navigation Links
ExonHit Therapeutics Shareholders' Equity Strengthened by Exercise of More Than Half of its Convertible Bonds
Date:3/8/2009

PARIS, March 9 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) today announced that 1,076,923 out of 2,080,335 convertible bonds issued November 8, 2006 and redeemable November 8, 2011 have been converted into shares.

This conversion results into a EUR 17,231 capital increase and EUR 6,982,769 increase in additional paid-in capital. At the same time, the convertible bond debt is reduced to EUR 6,522,178 compared to EUR 13,522,178 as of December 31, 2008.

Philippe Rousseau, Chief Financial Officer of ExonHit Therapeutics, said: "This transaction is good news for ExonHit, as it strengthens our balance sheet. And, while it is not providing any cash, this conversion will save us more than EUR 650,000 of interest payments over the next 32 months. "

About ExonHit Therapeutics

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit Therapeutics has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArray(TM) family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit Therapeutics has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers.

In parallel, ExonHit Therapeutics is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. ExonHit Therapeutics - 2007 Financial Results
7. ExonHit Appoints a New Management Board
8. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
9. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
10. Loic Maurel Joins Exonhit Therapeutics to Become CEO
11. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
(Date:12/24/2014)... 2014 On Friday, December 19, 2014, ... and Continuing Resolution Appropriations Act of 2015, which for ... receive funding through the Congressionally Directed Medical Research Programs ... Hydrocephalus Association (HA), working in conjunction with its allies ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... the National Institute of Standards and Technology (NIST) have ... go through an intersection while keeping their cool. Ten ... fact. The demonstration, described in a forthcoming paper in ... scaling up trap technology to build a large-scale quantum ...
... April 8 The University of Maryland today announces ... Business Plan Competition.Finalists present their ideas to a panel of new ... the University of Maryland, College Park . The competition is ... Information Technology Category include: , , ...
... DNA sequencing technology company, announced a definitive agreement ... investment in the company. Prompting its decision was ... reversible terminator chemistry, Lightning Terminators (TM), for ... chemistry as reagent kits to the market as ...
Cached Biology Technology:X marks the spot: Ions coldly go through NIST trap junction 2University of Maryland Announces Finalists for $75K Business Plan Competition 2University of Maryland Announces Finalists for $75K Business Plan Competition 3University of Maryland Announces Finalists for $75K Business Plan Competition 4University of Maryland Announces Finalists for $75K Business Plan Competition 5University of Maryland Announces Finalists for $75K Business Plan Competition 6SeqWright to Invest in LaserGen's Novel Lightning Terminators(TM) 2
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... from also becoming infected with hepatitis, researchers argue in a ... put people at higher risk of contracting HIV sharing ... also raise their risk of getting hepatitis B or ... be deadly. The study, which included all registered cases ...
... diseases like Alzheimer,s and Parkinson,s endogenous proteins accumulate in ... cells. These deposits, which consist of abnormally formed proteins, ... brain, thereby contributing to the development of the illness. ... and the US shows that certain protein particles are ...
... the genetic material of those animal and plant ... at the Institute of Molecular Genetics, Genetic Security ... (JGU) have developed a novel screening procedure that ... plant, and microbial substances present in foodstuffs. For ...
Cached Biology News:HIV sufferers need hepatitis safeguards 2Transmission routes of spreading protein particles 2New DNA test identifies ingredients in foods 2
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
...
...
... are predominantly used for labeling proteins, the ... peptides and nucleotides because they give better ... required in the conjugation processes. 5-TAMRA is ... peptides and proteins. 6-TAMRA is predominately used ...
Biology Products: